SLE and healthy control (HC) subject characteristics and KYN/TRP pathway metabolite ratios. All data is reported either as a mean (or median where indicated) ± standard deviation (or interquartile range), or as a frequency (%). All data refers to that which was collected at the time of evaluation
| Subject characteristics | SLE (N = 72) | HC (N = 73) | p |
|---|---|---|---|
| Age(mean # years ± SD, range) | 37.9 ± 9.6(22 – 57) | 36.2 ± 9.5(18 – 55) | 0.28 |
| Ethnicity (Hispanic/Latino) | 13 (18.1%) | 13 (17.8%) | 0.97 |
| Race Black | 43 (59.7%) | 41 (56.2%) | 0.91 |
| White | 16 (22.2%) | 18 (24.7%) | |
| Other | 13 (18.1%) | 14 (19.2%) | |
| KYN/TRP ratioMedian ± IQR (range) |
0.04 ± 0.03
(0.01 - 0.23) |
0.03 ± 0.01
(0.01 - 0.13) | <0.01 |
| QA/KA ratioMedian ± IQR (range) |
18.4 ± 14.7
(4.0 - 121.2) |
8.9 ± 5.8
(2.9 - 45.9) | <0.01 |
| Disease durationMean ± SD (range) | 12.3 ± 8.5(1 – 38) | n/a | n/a |
| SELENA SLEDAI scoreMean ± SD (range) | 5.4 ± 5.1(0 – 29) | n/a | n/a |
| Prednisone dose(mg/day; median ± IQR, range) | 2.5 ± 10.0(0 – 75) | n/a | n/a |
| Current hydroxychloroquine use | 54 (75.0%) | n/a | n/a |
| Current immunosuppressant use | 34 (47.2%) | n/a | n/a |
| Anti-dsDNA positive (> 29 IU/mL) | 50 (69.4%) | n/a | n/a |
| C3 low (< 81 mg/dL) | 28 (38.9%) | n/a | n/a |
| C4 low (< 13 mg/dL) | 24 (33.3%) | n/a | n/a |